M. Granger

发表

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium

S. Groshen, J. Maris, K. Matthay, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

131I‐MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma

R. Hawkins, K. Matthay, S. DuBois, 2013, Pediatric blood & cancer.

Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: A Pediatric Oncology Group study: A Report from the Children's Oncology Group

A. Naranjo, S. Grupp, L. Diller, 2012, Pediatric blood & cancer.

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Rachel A. Kudgus, S. Groshen, J. Maris, 2018, Clinical Cancer Research.

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

S. Groshen, R. Hawkins, K. Matthay, 2015, Clinical Cancer Research.

Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321)

T. Merchant, C. Rodríguez-Galindo, M. Chintagumpala, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).

A. Naranjo, W. London, R. Bagatell, 2018, European journal of cancer.

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group

A. Naranjo, J. Gastier-Foster, K. Matthay, 2017, Cancer.

Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor

Sara M. Federico, K. Somers, Sahr Yazdani, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children’s Oncology Group (COG) study.

A. Naranjo, J. Gastier-Foster, S. Grupp, 2016 .

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.

A. Naranjo, J. Gastier-Foster, D. von Allmen, 2021, Transplantation and cellular therapy.

Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures

David A. Edmondson, K. Matthay, D. Haas-Kogan, 2021, Radiation Research.

Racial and Ethnic Differences in Communication and Care for Children with Advanced Cancer.

H. Uno, L. Diller, S. Cohn, 2020, Journal of pain and symptom management.

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

S. Groshen, J. Maris, K. Matthay, 2023, Nature Medicine.

Unrealistic parental expectations for cure in poor‐prognosis childhood cancer

H. Uno, L. Diller, S. Cohn, 2020, Cancer.

Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group.

A. Naranjo, A. Mayampurath, S. Cohn, 2021, JCO clinical cancer informatics.